Zymeworks Inc

139 articles with Zymeworks Inc

• ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

  9/17/2020

   IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,  announce a research collaboration with Zymeworks Inc., giving ImmunoPrecise access to  Zymeworks' Azymetric™ and EFECT™ platforms for the

• Zymeworks Corporate Update Webcast and Conference Call Summary

  7/8/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today hosted a webcast and conference call highlighting its progress and key accomplishments in the first half of 2020.

• Zymeworks Announces New Multispecific Antibody Collaboration with Merck

  7/8/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longtime partner, Merck (known as MSD outside the US and Canada) have signed a new license agreement granting Merck the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric™ and EFECT™ platforms.

• Zymeworks Announces Corporate Update Webcast and Conference Call

  6/30/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that it will host a webcast and conference call to discuss progress on its corporate priorities and upcoming catalysts. Webcast and Conference Call Details Zymeworks will host a webcast and conference call on Wednesday, July 8, 2020 at 4:30pm ET (1:30pm PT). Interes

• Zymeworks to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/28/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Jefferies 2020 Virtual Healthcare Conference taking place June 2-4, 2020. The Company’s presentation will be on Thursday, June 4, 2020 at 2:30 p.m. ET. Interested parties can access a live webcast of the presentation via a link

• Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting - May 08, 2020

  5/8/2020

  Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 7, 2020.

• Zymeworks Reports 2020 First Quarter Financial Results

  5/7/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2020.

• Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene

  4/1/2020

  Zymeworks Inc. announced that its partner, BeiGene, Ltd., has dosed the first patient in a two-arm Phase 1b/2 trial evaluating Zymeworks’ HER2-targeted bispecific antibody ZW25 in combination with chemotherapy as a first-line treatment for patients with metastatic HER2-positive breast cancer and in combination with chemotherapy and BeiGene’s PD-1-targeted antibody tislelizumab as a first-line treatment for patients with metastatic HER2-positive gastroesophageal adenocarcinoma.

• Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors

  3/16/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Kelvin Neu, M.D., to its Board of Directors.

•  Zymeworks Reports 2019 Year-End Financial Results

  3/2/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2019. “

• Zymeworks to Present at Raymond James 41st Annual Institutional Investors Conference

  2/24/2020

  Feb. 24, 2020 13:30 UTC Zymeworks to Present at Raymond James 41 st Annual Institutional Investors Conference VANCOUVER, British Columbia--( BUSINESS WIRE )-- Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Raymond James Institutional Investors Conference taking place March 1-4, 2020 in Orlando, FL. The Company’s presentation will be on Monday, March 2

• Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Over-Allotment Option to Purchase Additional Shares - Jan. 27, 2020

  1/27/2020

  Zymeworks Inc., a clinical stage biopharmaceutical company developing multifunctional biotherapeutics, announced the closing of its previously announced underwritten public offering.

• Zymeworks Announces Pricing of $279.0 Million Public Offering

  1/23/2020

  Zymeworks Inc. announced the pricing of its previously-announced underwritten public offering of 4,924,729 common shares and, in lieu of common shares to a certain investor, pre-funded warrants to purchase up to 1,075,271 common shares.

• Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities

  1/13/2020

  Zymeworks also announced multiple clinical program advances for its lead candidates, ZW25 and ZW49.

• Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)

  1/12/2020

  Potential for a Novel Chemotherapy-Free Treatment Option for People with Advanced HER2-positive, HR-positive Breast Cancer

• Zymeworks to Present at the J.P. Morgan Healthcare Conference 2020

  1/7/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present a corporate overview and updated clinical development plans for its lead candidates ZW25 and ZW49 at the upcoming 38th Annual J.P. Morgan Healthcare Conference

• Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

  11/22/2019

  Zymeworks Inc. announced updated Phase 1 data for single agent ZW25 in heavily pretreated patients with HER2‑expressing solid tumors in a mini oral presentation by Dr. Do-Youn Oh, study investigator and Professor at Seoul National University, at the ESMO Asia 2019 Congress, taking place November 22 - 24 in Singapore.

• Zymeworks Reports 2019 Third Quarter Financial Results

  11/5/2019

  Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional therapeutics, reported financial results for the third quarter ended September 30, 2019.

• Zymeworks Files Automatic Shelf Registration Statement and Enters into At-The-Market Equity Offering Sales Agreement

  11/5/2019

  Zymeworks has become a “well-known seasoned issuer” under SEC rules and is filing the new Registration Statement to take advantage of certain benefits only available to WKSIs.

• Zymeworks to Present at Stifel 2019 Healthcare Conference

  11/4/2019

  Zymeworks Inc. announced that management will present at the upcoming Stifel 2019 Healthcare Conference taking place November 19-20, 2019 in New York, NY.